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Abstract
Background: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that
apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further
investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist,
TO901317.
Materials and methods: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor
(FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs.
The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1)
and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR.
Results: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and
SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with
guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover,
guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1.
Conclusion: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells
might be mediated via the LXR/FXR pathway.
Keywords: Liver X Receptor, Farnesoid X Receptor, Caco-2 cell line, Apolipoprotein M
Introduction
With the aging population and changing lifestyles, the inci-
dence of cardiovascular diseases (CVD) has gradually
increased [1]. Abnormal lipid metabolism has been consid-
ered as one of the major risk factors of CVD [2]. Previously
studies have demonstrated that serum concentrations of
apolipoprotein (apo) AI and apoB have significantly corre-
lation with the occurrences of CVD [3,4], and other apoli-
poproteins may also involve in the initiation and
progression of the diseases [5]. ApoM is one of the latest
discovered apolipoproteins that is mainly synthesized in
the liver, and to a smaller amounts, in the kidney [6].
In human plasma, most apoM are located in the high-
density lipoproteins (HDL) and small proportion present
also in apoB-containing lipoproteins, i.e. chylomicrons,
very low-, and low-density lipoproteins (VLDL and LDL)
[6,7]. Recent investigations have suggested that apoM may
participate in the HDL-related biological activities as an
important component of HDL particle on the protection of
endothelial cells [8]. Wolfrum, et al., [9] reported that
apoM is required for preb-HDL formation and cholesterol
efflux to HDL particles, which is an initial and crucial stage
of reverse cholesterol transport, and subsequently protects
against atherosclerosis. In addition, the physiological and
patho-physiological roles of apoM may also involve in the
inflammatory activities and the potential immuno- and
inflamm-reactive properties, and apoM may therefore con-
tribute to the anti-inflammatory function of HDL, being as
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mechanism [10,11].
ApoM could be regulated by many factors including
leptin, insulin, hyperglycemia and many cytokines in vivo
and in vitro [12]. It has been demonstrated that apoM
gene expression could be also affected by some nuclear
receptors, such as hepatocyte nuclear factor-1a (HNF-
1a) [13], hepatocyte nuclear factor-4a (HNF-4a)[ 1 2 ]
and liver receptor homolog-1 (LRH-1) [12]. Liver X
receptor (LXR) is a nuclear receptor, as a lipid sensor,
protects cells from lipid overload and directly or indir-
ectly controls apolipoprotein-mediated cholesterol efflux
[14]. Our previous studies demonstrated that the syn-
thetic LXR agonist TO901317 could down-regulate hepa-
tic apoM expression in vivo and in vitro [15]. Whereas
Calayir., et al. [16], in recognition of our findings that
TO901317 inhibited apoM expression in HepG2 cells,
even found that TO901317 could upregulate apoM
expression in intestinal cells. In the present study we
further revealed the regulative pathway of apoM expres-
sion in Caco-2 cells stimulated by TO901317.
Materials and methods
Cells and reagents
Human colorectal adenocarcinoma cell line, Caco-2, was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). TO901317 was purchased
from the Cayman Chemical Company (Ann Arbor, MI,
USA). Guggulsterone was from the Sigma Chemical Co.
Ltd. (Shanghai, China). Six-well cell culture clusters and
75 cm
2 vented cell culture flasks were purchased from
the Nunc (Roskilde, Denmark). Fetal bovine serum (FBS)
and Dulbecco’s Modified Eagle Medium (DMEM) were
obtained from the Invitrogen (Shanghai, China). Total
RNA purification kits were purchased from the Shenergy
Biocolor BioScience and Technology Company (Shang-
hai, China). First strand cDNA synthesis kits were
obtained from the Fermantas (Vilnius, Lithuania). The
LightCycler real-time RT-PCR System was from the
Roche Applied Science (Mannheim, Germany).
Cell cultures
Caco-2 cells were cultured in DMEM supplemented with
20% FBS in the presence of 100 U/ml penicillin, 100 μg/ml
streptomycin and 1% Glutamax at 37°C under 5% CO2
atmosphere. Cells were plated in 6-well cell culture clus-
ters at a density of 3 × 10
5 cells/dish with DMEM contain-
ing 20% FBS. Cell monolayer of approximately 50-70%
confluence were grown for 24 hrs in the above media
prior to experiments, cells were washed twice with phos-
phate buffered saline (PBS) and once with serum-free
DMEM without antibiotics. Then the experimental med-
ium, containing DMEM with 1% bovine serum albumin
(BSA) and different concentrations of TO901317 and gug-
gulsterone, or TO901317 together with guggulsterone
were added. As TO901317 must be dissolved in the
DMSO and then added into the experimental medium
(the final concentration of DMSO was at 1% in the present
study), 1% DMSO were always applied in the controls.
Unless stated otherwise, cells were incubated at 37°C for
24 hrs.
Total RNA extraction and real time RT-PCR
Total RNA of Caco-2 cells were extracted by using the
total RNA purification kit according to the manufac-
turer’s instructions. Primer Express software (Applied
Biosystems) was applied to design the primers and
probes of human apoM, apoA1, SHP1, LRH-1, ABCA1
and GAPDH (the sequences of primers and probes are
shown in Table 1). Quantifications of mRNA levels were
performed on a LightCycler in a final volume of 25 μl.
Optimal conditions were obtained with 2.5 μlo f1 0×
PCR buffer, 1.5 μlo f2 5m MM g C l 2,0 . 5μlo f1 0m M
4 × dNTPs, 0.25 μlo f5U / μl Taq DNA polymerase,
0.1 μl of 100 μM specific sense primer, 0.1 μl of 100 μM
specific antisense primer, 0.1 μlo f1 0 0μMs p e c i f i c
probe and 2 μl template cDNA. Finally 17.95 μlH 2O
was added to the reaction mixture. The thermal cycling
conditions for human apoM, apoA1, SHP1, LRH-1,
ABCA1 and GAPDH were as the following steps: 25°C
for 10 min, 48°C for 30 min and 95°C for 5 min to do
reverse transcription, and then the reaction mixture was
preheated for 2 min at 50°C and for 10 min at 95°C to
activate Taq polymerase. After that, a 40-cycle two step
PCR was performed consisting of 15s at 95°C and 1 min
at 60°C. Samples were amplified simultaneously in tripli-
cates in one-assay run. The prospective amplicon of
each gene was amplified and purified, then ligated into
the pMD19-T vector. The ligated product was trans-
formed into the E. Coli JM109 competent cells. In brief,
Table 1 Primers and fluorescent probes for real-time RT-PCR
Gene Forward primer Reverse primer Probe
GAPDH ggaaggtgaaggtcggagtc cgttctcagccttgacggt 5’-FAM-tttggtcgtattgggcgcctg-TAMRA
ApoM tgccccggaaatggatcta cagggcggccttcagtt 5’-FAM-cacctgactgaagggagcacagatctca-TAMRA
ApoA1 ctgggataacctggaaaaggagac ggaagtcgtccaggtagggct 5’-FAM-agatgagcaaggatctggaggaggtgaa-TAMRA
SHP1 aaagggaccatcctcttcaacc agggttccaggacttcacacag 5’-FAM-cctccaagccgcctcccacatt-TAMRA
LRH-1 ttagtggcaaaacttcgttctctcc agggcggcattgacttgttc 5’-FAM-agttcgtatgtctgaaattcttggtgctct-TAMRA
ABCA1 caaggggtaggagaaagagacgc ctcagccagcacccccag 5’-FAM-ccagccacggcgtccctgctgt-TAMRA
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Page 2 of 6a serial dilution of extracted plasmid DNA was used to
generate a standard curve by plotting the cycle threshold
versus the log initial copy number of input plasmid
DNA. Standard curves of apoM, apoA1, SHP1, LRH-1,
ABCA1 and GAPDH achieved a very high correlation
coefficient (r = 1.00). The ratio between the target gene
and GAPDH was calculated as the relative gene
expression.
Statistical analysis
Data are expressed as means ± SE. All experiments were
repeated twice and the data were represented one of the
experiments. Statistical analyses were performed with the
software Prism (version 5.0). Multiple comparisons were
performed with one-way ANOVA/dunnett-t, and com-
parisons between two groups were statistically evaluated
by the unpaired t-test. Significance was established at a P
value less than 0.05.
Results
As shown in Figure 1, TO901317 could significantly
upregulate mRNA levels of ABCA1, apoA1, apoM, LRH-
1 and SHP1 with dose-dependent manners. At 1.0 μM
TO901317, apoM mRNA level was increased by 24% (P <
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Figure 1 Effects of TO901317 on mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 in Caco-2 cells. Caco-2 cells were cultured with
different concentrations of TO901317 for 24 hrs. The mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were determined by real-time RT-
PCR in triplicates. The controls were represented as 100%. Data represents one of two similar experiments (means ± SE, n = 5). *p < 0.05; **p <
0.01; ***p< 0.001 vs. controls.
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Page 3 of 60.05), and at 5.0 μM TO901317, increased by more than
100% (P < 0.01) compared to the controls. When Caco-2
cells were cultured with guggulsterone alone, mRNA
levels of SHP1, LRH-1 and apoM were significantly
inhibited (P < 0.05); apoA1 decrease by 6% and 16%
respectively; However, ABCA1 were significant upregu-
lated (Figure 2), which were also dose dependents. As
s h o w ni nF i g u r e3 ,i td e m o n s t r a t e dt h a tg u g g u l s t e r o n e
could abolish TO901317 induced upregulation of apoA1,
SHP1, LRH-1 and apoM. When Caco-2 cells cultured
with 5 μM TO901317 together with 3.0 μg/ml guggul-
sterone, the mRNA levels of apoA1, SHP1, LRH-1 and
apoM were only 85%, 70%, 77% and 74% compared to
the cells cultured with TO901317 alone, respectively,
whereas ABCA1 were not affected compared to the cells
cultured with TO901317 alone (Figure 3).
Discussion
ApoM has firstly been identified from human postpran-
dial lipoproteins by Xu and Dahlbäck in 1999 [6].
Recent observations strongly suggest that apoM is pre-
dominantly confined to the HDL particles in human
plasma and it may have antiatherogenic properties invol-
ving in the conversion of large HDL to pre-b HDL, the
later mainly functions as an acceptor of peripherally
deposited cholesterol that is described as the revise cho-
lesterol transportation [9,17]. Moreover other researches
indicated that apoM might be also involved in the
immunity, inflammation, and neoplasia [18-20]. How-
ever, the physio-pathological functions of apoM are still
not fully revealed. Observation of the regulation of
apoM expression may reveal clinical importance of
apoM in humans.
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Figure 2 Effects of guggulsterone on mRNA levels of SHP1, LRH-1 and apoM in Caco-2 cells. Caco-2 cells were cultured with different
concentrations of guggulsterone for 24 hrs. The mRNA levels of ABCA1, apoA1, SHP1, LRH-1 and apoM were determined by real-time RT-PCR in
triplicates. The controls were represented as 100%. Data represents one of two similar experiments (means ± SE, n = 4-6). *p < 0.05; **p< 0.01;
***p< 0.001 vs. controls.
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Page 4 of 6Previous studies have demonstrated that hepatic apoM
expression could be regulated by certain cytokines and
nuclear factors. In our previous study [15], we demon-
strated that LXR agonist, TO901317, could significantly
downregulate apoM expression in the hepatic cell line,
HepG2 cells. Moreover, Calayir., et al. [16] confirmed our
findings that TO901317 did inhibit apoM expression in
HepG2 cells, however, they found that TO901317 could
significantly upregulate apoM expression in intestinal cell,
which suggest that TO901317 regulating apoM expression
is cellular dependent. Moreover, Mosialou., et al. [12]
reported that the natural LXR ligand oxysterols could sig-
nificantly upregulate apoM mRNA level and protein level
in HepG2 cells, and LXR could bind to the HRE in the
proximal apoM promoter examined by the Chromatin
Immunoprecipitation Assays( C H I P ) .T h e yf o u n dt h a t
TO901317 caused an increased mRNA level of Short Het-
erodimer Partner (SHP) in HepG2 cells. In contrast, the
SHP mRNA level was not affected by the oxysterols.
Enhanced expression of SHP could inhibit LRH-1-
mediated trans-activation of apoM promoter in HepG2
cells [11]. SHP is an inhibitory nuclear receptor activated
by the FXRs that interacts physically with many nuclear
receptors including LRH-1. Furthermore, it has been
reported that TO901317 is a dual LXR/FXR agonist that
activates FXR more efficiently than its natural ligand, the
bile acids [21]. Based on the findings described above, the
TO901317 downregulating apoM expression in hepatic
cells may be due to the activation of the FXR/SHP path-
way that inhibits LRH-1.
In the present studies, we further investigated effects of
TO901317 on apoM expression in Caco-2 cells mediated
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Figure 3 Inhibitory effects of guggulsterone on TO901317 induced expressions of SHP1, LRH-1 and apoM in Caco-2 cells. Caco-2 cells
were cultured with 5 μM TO901317 together with 3.0 μg/ml guggulsterone for 24 hrs. The mRNA levels of ABCA1, apoA1, SHP1, LRH-1 and
apoM were determined by real-time RT-PCR in triplicates. The cells cultured with TO901317 alone were represented as 100%. Data represents
one of two similar experiments (means ± SE, n = 4-6). *p < 0.05; **p< 0.01; ***p< 0.001 vs. controls.
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Page 5 of 6via the FXR/SHP/LRH-1 pathway. TO901317 could signif-
icantly upregulate the mRNA levels of ABCA1 that is a
classic LXR downstream gene [14]. LXR can bind to the
HRE upstream in the proximal apoM promoter to upregu-
late apoM gene expression. As SHP levels were enhanced
simultaneously and SHP is a classic FXR downstream
gene, which suggests that FXR has been activated simulta-
neously [22], whereas the LRH-1 was not inhibited by
the overexpressed SHP. LRH-1 was induced by the SHP
and the apoM mRNA levels were upregulated. The similar
phenomenon was seen in apoA1 expression [23],
TO901317 could downregulate apoA1 mRNA levels in
H e p G 2c e l l sb u ti tc o u l db eu p r e g u l a t e di nt h eC a c o - 2
cells. Furthermore we demonstrated that FXR antagonist,
guggulsterone, could abolish TO901317 increased expres-
sions of apoA1, apoM, SHP1 and LRH-1 in Caco-2 cells,
although guggulsterone alone might also decrease mRNA
levels of apoA1, apoM, SHP1 and LRH-1. All these find-
ings strongly suggest that activating FXR may mediate
upregulative apoM expression in the Caco-2 cells.
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